Efex 100mg Chewable Tablets for Dogs

Main information

  • Trade name:
  • Efex 100mg
  • Pharmaceutical form:
  • Chewable tablet
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Efex 100mg
    Germany
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • marbofloxacin
  • Therapeutic area:
  • Dogs Non Food

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0441/003
  • Authorization date:
  • 20-02-2013
  • EU code:
  • UK/V/0441/003
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

AN:00347/2013

Revised:August2013

Page 1 of 6

SUMMARYOFTHEPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Efex100mgchewabletabletsfordogs

Efexvet100mgchewabletabletsfordogs(FI,SE)

Axorvet100mgchewabletabletsfordogs(NO)

Axor100mgchewabletabletsfordogs(DK)

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Onetabletcontains:

Activesubstance:

Marbofloxacin..................................................100.0mg

Excipient(s):

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Chewabletablet

Clover-shapedscoredbeigetablet.Thetabletcanbedividedintofourequalparts

4. CLINICALPARTICULARS

4.1Targetspecies

Dogs

4.2Indicationsforuse,specifyingthetargetspecies

Indogs

Marbofloxacinisindicatedinthetreatmentof:

-skinandsofttissueinfections(skinfoldpyoderma,impetigo,folliculitis,

furunculosis,cellulitis)causedbysusceptiblestrainsoforganisms.

-urinarytractinfections(UTI)causedbysusceptiblestrainsoforganisms

associatedornotwithprostatitisorepididymitis.

-respiratorytractinfectionscausedbysusceptiblestrainsoforganisms.

4.3Contraindications

AN:00347/2013

Revised:August2013

Page 2 of 6

Donotuseindogsagedlessthan12months,orlessthan18monthsforgiant

breedsofdogswithalongergrowthperiod.

Donotuseincasesofhypersensitivityto(fluoro)quinolones.

4.4Specialwarningsforeachtargetspecies

AlowurinarypHcouldhaveaninhibitoryeffectontheactivityofmarbofloxacin.

4.5Specialprecautionsforuse

(i)Specialprecautionsforuseinanimals

Thechewabletabletsareflavoured.Inordertoavoidanyaccidentalingestion,

storetabletsoutofreachoftheanimals.

Thefluoroquinoloneshavebeenshowntoinduceerosionofarticularcartilagein

juveniledogsandcareshouldbetakentodoseaccuratelyespeciallyinyoung

animals.

Thefluoroquinolonesarealsoknownfortheirpotentialneurologicalsideeffects.

Cautioususeisrecommendedindogsandcatsdiagnosedassufferingfrom

epilepsy.

Fluoroquinolonesshouldbereservedforthetreatmentofclinicalconditionswhich

haverespondedpoorly,orareexpectedtorespondpoorlytootherclassesof

antimicrobials.Wheneverpossible,useoffluoroquinolonesshouldbebasedon

susceptibilitytesting.Useoftheproductdeviatingfromtheinstructionsgivenin

theSPCmayincreasetheprevalenceofbacteriaresistanttothe

fluoroquinolonesandmaydecreaseeffectivenessoftreatmentwithother

quinolonesduetothepotentialforcross-resistance.

Officialandlocalantimicrobialpoliciesshouldbetakenintoaccountwhenthe

productisused.

(ii)Specialprecautionstobetakenbythepersonadministeringthe

veterinarymedicinalproducttoanimals

Peoplewithknownhypersensitivityto(fluoro)quinolonesorothercomponentsof

theformulationshouldavoidusingthisproduct.Incaseofaccidentalingestion

seekmedicalattentionandshowproductlabeland/orpackageleaflettothe

doctor.Washhandsafteruse.

4.6Adversereactions(frequencyandseriousness)

Mildsideeffectsthatdonotnecessitatecessationoftreatmentsuchasvomiting,

softeningoffaeces,modificationofthirstortransientincreaseinactivitymay

occasionallyoccur.Thesesignsceasespontaneouslyaftertreatment.

4.7Useduringpregnancy,lactationorlay

Studiesinlaboratoryanimals(rat,rabbit)showednoembryotoxicity,

teratogenicityandmaternotoxicitywithmarbofloxacinattherapeuticdoses.

Howevernospecificstudieshavebeencarriedoutinpregnantandlactating

dogs.

Inpregnantandlactatinganimals,useonlyaccordingtothebenefit/risk

assessmentbytheresponsibleveterinarian.

AN:00347/2013

Revised:August2013

Page 3 of 6

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Fluoroquinolonesareknowntointeractwithorallyadministeredcations

(Aluminium,Calcium,Magnesium,Iron).Insuchcases,thebioavailabilitymaybe

reduced.

Concomitantadministrationoftheophyllinerequirescarefulmonitoringasserum

levelsoftheophyllinemayincrease.

4.9 Amountstobeadministeredandadministrationroute

Fororaladministration

Therecommendeddoserateis2mg/kg/d(1tabletfor50kgperday)insingle

dailyadministration.

Dogs:

-inskinandsofttissueinfections,treatmentdurationisatleast5days.

Dependingonthecourseofthedisease,itmaybeextendedupto40days.

-inurinarytractinfections,treatmentdurationisatleast10days.Dependingon

thecourseofthedisease,itmaybeextendedupto28days.

-inrespiratoryinfections,treatmentdurationisatleast7daysanddependingon

thecourseofthedisease,itmaybeextendedupto21days.

Bodyweight

(kg) Tablet

10.0-12.5 ¼

12.6 –25.0

½

25.1 –37.5 ¾

37.6 –50.0

1

50.1 –62.5 1¼

62.6 –75.0

75.1 –87.5 1¾

87.6 –100.0

2

Toensureacorrectdosagebodyweightshouldbedeterminedasaccuratelyas

possibletoavoidunderdosing.

Thechewabletabletsmaybeacceptedbydogsorcanbeadministereddirectly

intothemouthoftheanimals.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Overdosagemaycauseacutesignsintheformofneurologicaldisorders,which

shouldbetreatedsymptomatically.

4.11Withdrawalperiod(s)

Notapplicable.

AN:00347/2013

Revised:August2013

Page 4 of 6

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Antibacterialsforsystemicuse,fluoroquinolones

ATCvetcode:QJ01MA93

5.1 Pharmacodynamicproperties

Marbofloxacinisasynthetic,bactericidalantimicrobial,belongingtothe

fluoroquinolonegroupwhichactsbyinhibitionoftopoisomeraseII(DNAgyrase)

andtopoisomeraseIV..Ithasabroad-spectrumactivityinvitroagainstGram-

positivebacteria(inparticularStaphylococci,Streptococci)and,Gram-negative

bacteria(Escherichiacoli,Enterobactercloacae,Proteusspp,Klebsiellaspp,

Shigellaspp,Pasteurellaspp,Pseudomonasspp)aswellasMycoplasmaspp.

AreportonmicrobiologicalsusceptibilityincludingtwoEuropeanfieldsurveys

coveringhundredsofcanineandfelinepathogenssensitivetomarbofloxacinwas

publishedon2009

Micro-organisms MIC(µg/ml)

Staphylococcus

intermedius 0,23-0,25

Escherichiacoli 0,125-0,25

Pasteurellamultocida 0,04

Pseudomonas

aeruginosa 0,94

CasesofresistancehavebeenobservedinStreptococcus.StrainswithMIC≤1

µg/mlaresensitivetomarbofloxacinwhereasstrainswithMIC≥4µg/mlare

resistanttomarbofloxacin.

Marbofloxacinisnotactiveagainstanaerobes,yeastsorfungi.

Theactivityofmarbofloxacinagainstthetargetbacterialspeciesisbactericidal

concentration-dependant.

Resistancetofluoroquinolonesoccursbychromosomalmutationwiththree

mechanisms:decreaseofthebacterialwallpermeability,expressionofefflux

pumpormutationofenzymesresponsibleformoleculebinding.Todate,only

sporadiccaseshavebeenreportedforplasmidmediatedfluoroquinolone

resistanceinanimals.Dependingontheunderlyingresistancemechanismcross-

resistancetoother(fluoro)quinolonesandco-resistancetootherantimicrobial

classescanoccur.

AN:00347/2013

Revised:August2013

Page 5 of 6

5.2Pharmacokineticparticulars

Afteroraladministrationindogsattherecommendeddoseof2mg/kg,

marbofloxacinisreadilyabsorbedandreachesmaximalplasmaconcentrationsof

1.5µg/mlwithin2hours

Itsbioavailabilityiscloseto100%.

Itisweaklyboundtoplasmaproteins(lessthan10%),extensivelydistributedand

inmosttissues(liver,kidney,skin,lung,bladder,digestivetract)itachieveshigher

concentrationsthaninplasma.Marbofloxaciniseliminatedslowly(t½ß=14hin

dogs)predominantlyintheactiveforminurine(2/3)andfaeces(1/3).

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Lactosemonohydrate

Copovidone

Silica,colloidalanhydrous

Croscarmellosesodium

Hydrogenatedcasteroil

Pigliverpowder

Maltedyeast

Cellulosemicrocrystalline

6.2Incompatibilities

Notapplicable

6.3Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:

Blister:PVC-TE-PVDC –aluminiumheatsealed:24months

Blister:PA-AL-PVC –aluminiumheatsealed:36months

Shelf-lifeafterfirstopeningtheimmediatepackaging:72hours:

6.4.Specialprecautionsforstorage

Blister:PVC-TE-PVDC –aluminiumheatsealed: Donotstoreabove30°C

Blister:PA-AL-PVC –aluminiumheatsealed:Thisveterinarymedicinalproduct

doesnotrequireanyspecialtemperaturestorageconditions.

Tabletportionsshouldbestoredintheblisterpack

Anytabletportionsremainingafter72hoursshouldbediscarded

Keeptheblisterintheoutercarton.

AN:00347/2013

Revised:August2013

Page 6 of 6

6.5Natureandcompositionofimmediatepackaging

(Polyvinylchloride-Thermo-elast-Polyvinylidenechloride –aluminiumheat

sealed)containing6tabletsperblister

(Polyamide-Aluminium-Polyvinylchloride –aluminiumheatsealed)

containing6tabletsperblister

Cardboardboxof6tabletscontaining1blisterof6tablets

Cardboardboxof12tabletscontaining2blistersof6tablets

Cardboardboxof120tabletscontaining20blistersof6tablets

Cardboardboxof240tabletscontaining40blistersof6tablets

Notallpacksizesmaybemarketed.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductsshouldbedisposedofinaccordancewithlocal

requirements.

7. MARKETINGAUTHORISATIONHOLDER

SOGEVAL

200avenuedeMayenne

ZoneIndustrielledesTouches

53000LAVAL

FRANCE

Tel:33243495151

Fax:33243539700

E-mail: sogeval@sogeval.fr

8. MARKETINGAUTHORISATIONNUMBER

20749/4032

9. DATEOFFIRSTAUTHORISATION

August2013

10 DATEOFREVISIONOFTHETEXT

August2013

Approved:01/08/2013

7-12-2018

Magnesium citrate malate as a source of magnesium added for nutritional purposes to food supplements

Magnesium citrate malate as a source of magnesium added for nutritional purposes to food supplements

Published on: Thu, 06 Dec 2018 The present scientific opinion deals with the assessment of the bioavailability of magnesium, from the proposed nutrient source, magnesium citrate malate (MgCM), when added for nutritional purposes to food supplements. MgCM is a mixed salt consisting of magnesium cations and citrate and malate anions, and with a magnesium content of 12–15%. MgCM is proposed to be used in food supplements that are intended to provide up to 300–540 mg/day magnesium. The data provided demonst...

Europe - EFSA - European Food Safety Authority Publications

4-12-2018

FDA Approves Pexion for Treating Noise Aversion in Dogs

FDA Approves Pexion for Treating Noise Aversion in Dogs

The U.S. Food and Drug Administration announced today that its Center for Veterinary Medicine has approved Pexion (imepitoin tablets) to treat noise aversion in dogs. Dogs with noise aversion are sensitive to loud noises such as fireworks, street/traffic noises, and gun shots.

FDA - U.S. Food and Drug Administration

22-11-2018

Safety and efficacy of Monteban® G100 (narasin) for ducks for fattening

Safety and efficacy of Monteban® G100 (narasin) for ducks for fattening

Published on: Wed, 21 Nov 2018 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of Monteban® G100 for ducks. Monteban® G100, containing narasin, is intended for the prevention of coccidiosis in ducks for fattening at a dose range of 60–70 mg/kg of complete feed. Narasin from Monteban® G100 is safe for ducks for fattening at a level of 70 mg/kg complete feed...

Europe - EFSA - European Food Safety Authority Publications

21-11-2018

Safety and efficacy of Monteban® G100 (narasin) for chickens for fattening

Safety and efficacy of Monteban® G100 (narasin) for chickens for fattening

Published on: Tue, 20 Nov 2018 The feed additive Monteban® G100, containing the active substance narasin, an ionophore anticoccidial, is intended to control coccidiosis in chickens for fattening at a dose of 60–70 mg/kg complete feed. Narasin is produced by fermentation. Limited data on the taxonomic identification of the production strain did not allow the proper identification of strain NRRL 8092 as Streptomyces aureofaciens. The FEEDAP Panel cannot conclude on the absence of genetic determinants for ...

Europe - EFSA - European Food Safety Authority Publications

9-11-2018

Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Losartan Potassium and Hydrochlorothiazide Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API)

Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Losartan Potassium and Hydrochlorothiazide Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API)

Sandoz Inc. is voluntarily recalling one lot of Losartan Potassium Hydrochlorothiazide Tablets, USP 100mg/25mg to the consumer level. This product is being recalled due to the trace amount of an impurity, N-nitrosodiethylamine (NDEA) contained in the API Losartan, USP manufactured by Zhejiang Huahai Pharmaceutical Co. Ltd. Sandoz Inc. Losartan Potassium Hydrochlorothiazide product is manufactured by Lek Pharmaceuticals dd, Ljubljana, Slovenia. This impurity, which is a substance that occurs naturally in ...

FDA - U.S. Food and Drug Administration

9-11-2018

Safety assessment of the substance Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials

Safety assessment of the substance Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials

Published on: Wed, 07 Nov 2018 00:00:00 +0100 The EFSA Panel on Food Contact Materials, Enzymes and Processing Aids (CEP Panel) assessed the safety of the additive Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials. It is a family of mixtures combining the four lanthanides lanthanum (La), europium (Eu), gadolinium (Gd) and/or terbium (Tb) in different proportions as their 1,4‐benzene dicarboxylate complexes, used as a taggant in plastics for authentication and ...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Efficacy of Bergazym® P100 (endo‐1,4‐β‐xylanase) as a feed additive for chickens for fattening and weaned piglets

Efficacy of Bergazym® P100 (endo‐1,4‐β‐xylanase) as a feed additive for chickens for fattening and weaned piglets

Published on: Tue, 30 Oct 2018 00:00:00 +0100 The product Bergazym® P100 contains a xylanase which is produced by a non‐genetically modified strain of Trichoderma reesei. The additive is available in a coated granular form and it is intended to be used as a zootechnical additive (functional group: digestibility enhancers) for chickens for fattening, and weaned piglets at the dose of 1,500 EPU/kg feed. The production strain and the additive were fully characterised in a previous assessment of the Panel o...

Europe - EFSA - European Food Safety Authority Publications

28-9-2018

Endo Pharmaceuticals Issues Voluntary Nationwide Recall for Two Lots of Robaxin® 750mg Tablets 100 Count Bottle Packs Due to Incorrect Daily Dosing Information on Label

Endo Pharmaceuticals Issues Voluntary Nationwide Recall for Two Lots of Robaxin® 750mg Tablets 100 Count Bottle Packs Due to Incorrect Daily Dosing Information on Label

Endo International plc (NASDAQ: ENDP) today announced that one of its operating companies, Endo Pharmaceuticals Inc., is voluntarily recalling two lots of Robaxin® (methocarbamol tablets, USP) 750mg Tablets 100 Count Bottle pack to the consumer level. The products have been found to have incorrect daily dosing information on the label due to a labeling error which misstates the daily dose as "two to four tablets four times daily" rather than the correct dosage of "two tablets three times daily." (see pic...

FDA - U.S. Food and Drug Administration

7-9-2018

SCA Pharmaceuticals LLC. Issues Voluntary Nationwide Recall of Furosemide 100 mg in 0.9% Sodium Chloride due to Presence of Precipitate

SCA Pharmaceuticals LLC. Issues Voluntary Nationwide Recall of Furosemide 100 mg in 0.9% Sodium Chloride due to Presence of Precipitate

, SCA Pharmaceuticals LLC (“SCA Pharma”) is voluntarily recalling 7 lots of the injectable product Furosemide 100 mg in 0.9% Sodium Chloride 100 mg bag to the consumer level. This product is being recalled for visible particulate matter believed to be furosemide precipitate.

FDA - U.S. Food and Drug Administration

28-8-2018

Accord Healthcare Inc. Issues Voluntary Nationwide Recall of Hydrochlorothiazide Tablets USP 12.5 Mg Due to Labeling Mix-up

Accord Healthcare Inc. Issues Voluntary Nationwide Recall of Hydrochlorothiazide Tablets USP 12.5 Mg Due to Labeling Mix-up

A 100 count bottle of Hydrochlorothiazide Tablets USP 12.5 mg has been found to contain 100 Spironolactone Tablets USP 25 mg. Since the individual lot, PW05264, of the product is involved in a potential mix-up of labeling, Accord is recalling this individual lot from the market.

FDA - U.S. Food and Drug Administration

14-8-2018

World Organix, LLC Issues Voluntary Nationwide Recall of Blissful Remedies Red Maeng Da 100% Mitragyna Speciosa, Blissful Remedies Red Maeng Da Liquid Kratom Mitragyna Speciosa, Blissful Remedies 4 Hour Chill Slow Motion Blend, Due to High Microbial Loads

World Organix, LLC Issues Voluntary Nationwide Recall of Blissful Remedies Red Maeng Da 100% Mitragyna Speciosa, Blissful Remedies Red Maeng Da Liquid Kratom Mitragyna Speciosa, Blissful Remedies 4 Hour Chill Slow Motion Blend, Due to High Microbial Loads

World Organix LLC, is voluntarily recalling lot: 112710 of Blissful Remedies Red Maeng Da 100% Mitragyna Speciosa capsules, Blissful Remedies Red Maeng Da Liquid Kratom Mitragyna Speciosa, Blissful Remedies 4 Hour Chill Slow Motion Blend to the consumer level. These products have been tested by the U.S. Food and Drug Administration (“FDA”) and found to be contaminated with High Microbial Loads. Additionally, this serves as a update to a previous press release posted on June 30th 2018, concerning Blissful...

FDA - U.S. Food and Drug Administration

3-8-2018

Scientific guideline:  Posaconazole gastro-resistant tablet 100 mg product-specific bioequivalence guidance, adopted

Scientific guideline: Posaconazole gastro-resistant tablet 100 mg product-specific bioequivalence guidance, adopted

Posaconazole gastro-resistant tablet 100 mg product-specific bioequivalence guidance

Europe - EFSA - European Food Safety Authority EFSA Journal

18-7-2018

FDA Approves NexGard for prevention of infections that cause Lyme disease in dogs

FDA Approves NexGard for prevention of infections that cause Lyme disease in dogs

FDA has approved NexGard (afoxolaner), a chewable tablet administered once monthly to dogs, for the prevention of Borrelia burgdorferi (B. burgdorferi) infections by killing Black-legged ticks (Ixodes scapularis), which carry the bacterium.

FDA - U.S. Food and Drug Administration

22-6-2018

Metronidazole intravenous infusion 500 mg/100 mL bag

Metronidazole intravenous infusion 500 mg/100 mL bag

Shortage and althernative supply of Metronidazole intravenous infusion 500 mg/100 mL bag

Therapeutic Goods Administration - Australia

15-6-2018

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

At least 43 patient reported adverse event after receiving eye injections of Guardian’s Pharmacy Services compounded triamcinolone-moxifloxacin product during cataract surgery. The patients reportedly experienced various symptoms, including vision impairment, poor night vision, loss of color perception, and significant reductions in best-corrected visual acuity and visual fields. FDA identified multiple substances in Guardian’s product, including poloxamer 407 and poloxamer 407 degradants. FDA prepared i...

FDA - U.S. Food and Drug Administration

28-2-2018

Help 100% & Pure Natural & Body Slim capsules

Help 100% & Pure Natural & Body Slim capsules

Help 100% & Pure Natural & Body Slim Capsules pose a serious risk to your health and should not be taken

Therapeutic Goods Administration - Australia

12-12-2018

Therapeutic Goods (Microbiological Standards for Medicines) (TGO 100) Order 2018

Therapeutic Goods (Microbiological Standards for Medicines) (TGO 100) Order 2018

TGO 100 has been registered on the Federal Register of Legislation. It commences on 8 December 2018, repealing and replacing TGO 98

Therapeutic Goods Administration - Australia

21-11-2018

EU/3/18/2100 (Quality Regulatory Clinical Ireland Limited)

EU/3/18/2100 (Quality Regulatory Clinical Ireland Limited)

EU/3/18/2100 (Active substance: Propagermanium) - Orphan designation - Commission Decision (2018)7810 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/103/18

Europe -DG Health and Food Safety

27-7-2018

EU/3/12/1003 (bluebird bio (Germany) GmbH)

EU/3/12/1003 (bluebird bio (Germany) GmbH)

EU/3/12/1003 (Active substance: Autologous haematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ABCD1 cDNA) - Transfer of orphan designation - Commission Decision (2018)5033 of Fri, 27 Jul 2018 European Medicines Agency (EMA) procedure number: EMA/OD/009/12/T/01

Europe -DG Health and Food Safety